PedAM
Pediatric Disease Annotations & Medicines
| Disease | cystic fibrosis |
| Symptom | |lung infection |
| Sentences | 73 |
| PubMedID- 21930755 | Genotypic and phenotypic variation in pseudomonas aeruginosa reveals signatures of secondary infection and mutator activity in certain cystic fibrosis patients with chronic lung infections. |
| PubMedID- 25443661 | Nocardia farcinica lung infection in a patient with cystic fibrosis and a lung transplant. |
| PubMedID- 23281188 | In chronic lung infections of people with cystic fibrosis, p. aeruginosa inhabits viscous, adhesive mucus, which likely retards the diffusion of secreted molecules. |
| PubMedID- 25470304 | Objectives: the objective of our review was to compare antibiotic treatment to no antibiotic treatment, or to compare different combinations of antibiotic treatment, for nontuberculous mycobacteria lung infections in people with cystic fibrosis. |
| PubMedID- 22973562 | Historically, pharmaceutical aerosols have been employed for the treatment of obstructive airway diseases, such as asthma and chronic obstructive pulmonary disease, but in the past decades their use has been expanded to treat lung infections associated with cystic fibrosis and other respiratory diseases. |
| PubMedID- 21303421 | Biofilm-associated chronic pseudomonas aeruginosa lung infections in patients with cystic fibrosis are virtually impossible to eradicate with antibiotics because biofilm-growing bacteria are highly tolerant to antibiotics and host defense mechanisms. |
| PubMedID- 20503281 | Pseudomonas aeruginosa (psa) is the most common pathogen to cause chronic lung infection in children with cystic fibrosis (cf), and is associated with an increase in both morbidity and mortality. |
| PubMedID- 20211000 | Nocardia farcinica lung infection in a patient with cystic fibrosis: a case report. |
| PubMedID- 20951086 | Murine models of acute and chronic lung infection with cystic fibrosis pathogens. |
| PubMedID- 22679547 | Patients who have end stage lung diseases such as cystic fibrosis, bronchiectasia along with secondary lung infections need lung transplantation to prolong their life. |
| PubMedID- 20927769 | Authors' conclusions: we could not identify an antibiotic adjuvant therapy that could be recommended for the treatment of lung infection in those with cystic fibrosis. |
| PubMedID- 23533140 | Overproduction of alginate, also known as mucoidy, affords the bacterium protection from the host's defenses and facilitates the establishment of chronic lung infections in individuals with cystic fibrosis. |
| PubMedID- 25861288 | During the last 2 decades, colistin was mainly restricted to treat acute exacerbations of lung infections in patients with cystic fibrosis . |
| PubMedID- 25657265 | Pandoraea is an emerging respiratory pathogen capable of causing chronic lung infections in people with cystic fibrosis (cf), but the clinical significance of this infection is ambiguous. |
| PubMedID- 23848942 | The membrane filter biofilm model mirrored biofilms in environmental habitats as found in soil or on leaves and also biofilms involved in infections as for example lung infections of cystic fibrosis patients . |
| PubMedID- 24454693 | P. aeruginosa is also widely studied as an opportunistic pathogen of plants, animals and humans and in particular, as a pathogen causing persistent and frequently fatal lung infections in patients with cystic fibrosis (cf) 8. |
| PubMedID- 25806622 | Biofilms play important roles in human infections including native valve endocarditis, otitis media, chronic bacterial prostatitis, lung infections in patients with cystic fibrosis and periodontitis . |
| PubMedID- 22022288 | Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review. |
| PubMedID- 26268854 | The opportunistic pathogen pseudomonas aeruginosa causes chronic lung infection in patients with cystic fibrosis. |
| PubMedID- 22715310 | S. aureusis causing a range of acute and pyogenic infections, includingabscesses, central nervous system infections, endocarditis,osteomyelitis, pneumonia, urinary tract infections, chroniclung infections associated with cystic fibrosis, and severalsyndromes caused by exotoxins and enterotoxins, includingfood poisoning, scalded skin and toxic shock syndromes 1. |
| PubMedID- 26223882 | Pseudomonas aeruginosa (pa) is an opportunistic gram-negative pathogen associated with nosocomial infections, acute infections and chronic lung infections in patients with cystic fibrosis. |
| PubMedID- 26253522 | Pseudomonas aeruginosa causes chronic lung infections in people with cystic fibrosis (cf) and acute opportunistic infections in people without cf. |
| PubMedID- 22905192 | It is a leading cause of acute pneumonia in hospitalized patients and is responsible for chronic lung infection in patients with cystic fibrosis. |
| PubMedID- 21926193 | Although only poorly documented, it can be assumed that intensive antibiotic treatments of chronic lung infections in patients with cystic fibrosis (cf) also affect the diversity and metabolic functioning of the gastrointestinal microbiota and potentially lead to a state of dysbiosis. |
| PubMedID- 24015256 | Pseudomonas aeruginosa (pa) is an important bacterial pathogen causing acute nosocomial infections in immunocompromised patients, and chronic recurring lung infections in patients with cystic fibrosis (cf) or non-cf bronchiectasis . |
| PubMedID- 25786110 | In humans, genetic evidence of the relevance of ptx3 in innate resistance has been described in pulmonary tuberculosis, in cystic fibrosis patients with p. aeruginosa lung infection and in invasive aspergillosis in patients undergoing hematopoietic stem-cell transplantation . |
| PubMedID- 20644645 | Clinical scvs are usually isolated from patients suffering from chronic infections (e.g., from lung infections due to cystic fibrosis or from osteomyelitis) . |
| PubMedID- 23235684 | Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. |
| PubMedID- 23403223 | Background: mycobacterium abscessus causes lung infection in patients with cystic fibrosis. |
| PubMedID- 25705428 | In the last decade, many studies published the use of colistin in the treatment of lung infection in patients without cystic fibrosis, with conflicting results. |
| PubMedID- 25494960 | The ecotypes isolated from this long-term experimental evolution are similar to those commonly isolated from lung infections of persons with cystic fibrosis (cf) (zlosnik et al. |
| PubMedID- 24034668 | It is responsible for serious chronic and often fatal lung infections in patients with cystic fibrosis and acute infections in patients that are immune compromised or have serious burns 1. |
| PubMedID- 20352425 | For example, while pyo production by p. aeruginosa during lung infection of cystic fibrosis patients is correlated with a poor prognosis, it is also highly correlated with a lower incidence of yeast infections (lau et al. |
| PubMedID- 20948804 | It is also the leading bacterial cause of acute ventilator-associated pneumonia and chronic lung infections in patients with cystic fibrosis (cf). |
| PubMedID- 22230402 | Aeruginosa causes chronic lung infection in individuals with cystic fibrosis and nosocomial pneumonia resulting in significant morbidity and mortality. |
| PubMedID- 26430738 | P. aeruginosa causes life-threatening community-acquired pneumonia, nosocomial infections such as pneumonia, urinary tract infections, and bacteremia; and chronic lung infections in patients with cystic fibrosis 7. |
| PubMedID- 22540844 | In conclusion, these data underline the importance of biofilm prevention strategies by early aggressive antibiotic prophylaxis or therapy before phenotypic diversification during chronic lung infection of patients with cystic fibrosis. |
| PubMedID- 20019078 | During the chronic lung infection of patients with cystic fibrosis (cf), pseudomonas aeruginosa can survive for long periods due to adaptive evolution mediated by genetic variation. |
| PubMedID- 20934258 | Pseudomonas aeruginosa is the major pathogen of chronic lung infections in individuals with cystic fibrosis (cf). |
| PubMedID- 24709961 | These strains are genetically diverse, differ from strains that cause chronic lung infections in patients with cystic fibrosis, and exhibit heterogeneous production of virulence factors in vitro. |
| PubMedID- 21178134 | Tobramycin inhalation solution usp (tobi), a therapy developed to treat lung infections associated with cystic fibrosis (cf), was presented as a demonstration case for collaborative pharmaceutical development at a clinical and translational science awards industry forum on "promoting efficient and effective collaborations among academia, government, and industry" held in february 2010. |
| PubMedID- 22767545 | Burkholderia cenocepacia is a member of the burkholderia cepacia complex (bcc), a group of gram-negative opportunistic pathogens that cause severe lung infections in patients with cystic fibrosis and display extreme intrinsic resistance to antibiotics, including antimicrobial peptides. |
| PubMedID- 23481089 | However whether and how it can be used for the treatment of bacterial lung infections in patients with cystic fibrosis is unclear. |
| PubMedID- 25036925 | Chronic bacterial lung infections associated with non-cystic fibrosis bronchiectasis represent a substantial and growing health-care burden. |
| PubMedID- 25147668 | One of the most medically important biofilm-forming species is pseudomonas aeruginosa, which is commonly associated with lung infections in patients with cystic fibrosis. |
| PubMedID- 25221853 | Purpose of review: newer 'innovative' formulations of antibiotics for pseudomonas aeruginosa lung infection in patients with cystic fibrosis include colistimethate sodium and tobramycin in the form of dry powders for inhalation (dpis). |
| PubMedID- 23029239 | For example, high persistence mutants have been isolated from cystic fibrosis patients with lung infections and from patients with candidiasis . |
| PubMedID- 23486248 | Cenocepacia is known for its ability to cause lung infections in people with cystic fibrosis and it possesses a large 8 mb multireplicon genome encoding a wide array of pathogenicity and fitness genes. |
| PubMedID- 25957311 | From clinical infections, including the chronic bacterial lung infections associated with cystic fibrosis that form a focus of my research, there is now abundant evidence suggesting that rapid evolution by infecting microbes contributes to host adaptation, treatment failure and worsening patient prognosis. |
| PubMedID- 22208544 | Commercial availability of more than one inhaled antibiotic for the management of chronic pseudomonas aeruginosa lung infections in persons with cystic fibrosis creates a welcome question: can different inhaled therapies be combined to improve patient outcomes. |
Page: 1 2